65,437 trials
Irritable Bowel Syndrome
Primary: Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2) — 17.57; 16.2; 18.76 mL/mm Hg
Pancreatic Cancer
Primary: Determination of Maximum Tolerated Dose (MTD), The Dose of Study Drug(s) Which Causes <33% of Patients Treated to Experience Unacceptable Side Effects — 10; 1000…
Heart Failure
Primary: Change in Serum Potassium — 0.15; 0.05 mg/dl
Female Stress Urinary Incontinence
Primary: International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ-UI SF) — 10.3; 10.4; 7.3; 6.9 units on a scale — p=0.27
Multifocal Motor Neuropathy
Primary: Grip Strength in the More Affected Hand — 18.14; 21.68; 19.54; 19.39 kilograms
Bronchopulmonary Dysplasia
Primary: Number of Days Being Intubated — 12.4; 6.2 days
Muscular Atrophy, Spinal
Primary: Strength — 0.39 kilograms
Influenza
Primary: Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against the 3 Fluarix Vaccine Strains. — 22.2; 21.6; 173.8; 176.9 titers
Obsessive-Compulsive Disorder
Primary: Clinical Global Impression - Severity of Activation (CGI-SA) — .50; 2.00; 2.00 units on a scale — p=.2106
Chronic Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 participants
Sarcoma
Primary: Occurrence of Severe Toxicity — 1; 1 participants
Hemoglobinopathies · Sickle Cell Disease · Thalassemia
Primary: Stable Engraftment With Donor Stem Cells in Patients With Severe Hemoglobinopathy. — 2 participants
Rheumatoid Arthritis
Primary: Serum Progesterone Level — 0.21; 0.57; 0.22; NA ng/mL
Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Each Hour Evaluated at Week 12 — 25.41; 25.38; 24.79; 24.72 mm Hg
Urinary Bladder, Overactive
Primary: Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours — 3.93; 1.60 episodes per 24 hours — p=<0.0001